Answers are grounded in this paper and cite their sources.
Abstract ID 128664 Poster Board 163 Regulator of G protein Signaling (RGS) proteins negatively modulate signaling downstream of G protein-coupled receptors (GPCRs) by accelerating GTP hydrolysis at G α subunits of heterotrimeric G proteins. As such, they represent novel alternatives to current approaches targeting GPCR signaling. While research on RGS proteins and how they are regulated has expanded rapidly in recent years, large gaps still remain regarding specific mechanisms of regulation for the majority of RGS proteins. As a multitude of pathologies have been linked to reduced expression and/or function of one or more RGS proteins, identifying selective mechanisms that regulate individual RGS proteins will open for novel therapeutic strategies. One example is RGS2, which is selective for G αq signaling. Decreased RGS2 levels are implicated in numerous diseases, including cardiovascular disease, asthma, and several types of cancer. Thus, identifying selective means of enhancing RGS2 protein levels would be a viable therapeutic strategy. RGS2 is rapidly degraded through the ubiquitin-proteasomal pathway, and we previously identified F-box only protein 44 (FBXO44) as the substrate recognition component of the E3 ligase responsible for facilitating RGS2 degradation. As such, the RGS2-FBXO44 interaction is a potential target for pharmacological intervention. Detailed information on the FBXO44 recognition site (degron) in RGS2 will aid in structure-based small molecule inhibitor design, as well as in identifying additional FBXO44 targets, which would help predict possible side effects of targeting this interaction. We previously determined that FBXO44 binds RGS2 through a short degron motif near the RGS2 N-terminus. The degron in the only other known FBXO44 substrate, BRCA1, remains unidentified, only narrowed down to the first 167 N-terminal residues. The exact sequence of the RGS2 degron is absent within this region in BRCA1. However, identifying what chemical properties are important for FBXO44-mediated degradation of RGS2 may provide predictive tools for identifying the degron sequence of BRCA1, as well as other potential FBXO44 substrates. Thus, the goal of this study was to dissect the molecular properties for FBXO44 binding of the RGS2 degron. First, we used an in vitro peptide array utilizing systemic residue substitution and identified several amino acid changes that altered binding both positively and negatively. In the absence of structural data, we then created an in silico model using AlphaFold prediction and used molecular dynamics simulations to further examine how this interaction occurs and generate further hypotheses for testing. Finally, we experimentally confirmed our results in cells through co-immunoprecipitation and proteasomal inhibition, using mutated full-length RGS2. Several substitutions were fairly tolerated and resulted in little to no effect on the RGS2-FBXO44 interaction. However, Cys¹³ is a crucial component of the degron and mutation to a Ser completely abolished the interaction. Furthermore, Arg substitutions at several positions significantly enhanced the interaction with FBXO44, indicating that a positive charge is beneficial. These results provide structural insights into RGS2-FBXO44 binding, which will aid in structure-based drug discovery efforts. It also provides a framework for building a consensus recognition motif for FBXO44, which could aid in identifying more substrates for this understudied F-box protein. R01GM143493
No takes yet. Share an insight, caveat, or question.
McNabb et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: